The U.S. Food and Drug Administration (FDA) has expanded the approval for the popular injectable weight-loss drug Wegovy (semaglutide) to include the treatment of a serious form of fatty liver disease known as metabolic-associated steatohepatitis (MASH). This condition was also previously called nonalcoholic steatohepatitis (NASH). Specifically, the accelerated approval was to treat MASH in adults […] The post FDA approves Wegovy for liver disease appeared first on The Checkup.
